PHARE trial results comparing 6 to 12 months of adjuvant trastuzumab in early breast cancer

An academic randomized, non-inferiority trial conducted by the French National Cancer Institute (INCa) has compared a shorter trastuzumab exposure of 6 months versus the standard 12 months treatment. The PHARE trial addressed the question of duration of adjuvant treatment by trastuzumab in HER2-positive early breast cancer. The results are presented at Presidential Symposium of the ESMO 2012 Congress in Vienna. Read more here.